the chains of
Feb. 2, 2021
May 15, 2018
Aether Therapeutics, an Austin-based, innovative new biotech company developing a first-in-class preventive treatment for Neonatal Abstinence Syndrome, was awarded a Fast-Track Small Business Innovation Research (SBIR) Grant from the National Institute of Drug Abuse (NIDA).
July 1, 2018
Aether Therapeutics announced today it has finalized the negotiations with The Ohio State University as part of its effort to secure the exclusive license for the use of 6BN for the treatment and avoidance of neonatal abstinence syndrome.
July 22, 2018
Aether Therapeutics has partnered with Ohio's three Neonatal Research Centers as part of a collaborative clinical developmental effort, which will ensure the ability to recruit patients under excellent resource conditions including facilities, key subject matter experts, clinical protocols, and standardized treatment protocols developed by the OPQC. Ohio has been one of the hardest hit states by the opioid epidemic, but has also been a leading state in the development of standard of care for treating babies exposed to opioids.
Aether CSO, Wolfgang Sadee, invited to present Research at Annual APS Meeting in Philly
March 21, 2021
World Class Collaborators
Neonatal centers in Ohio have worked collaboratively over the last 6 years to improve the care of infants with neonatal abstinence syndrome (NAS). In a series of projects, Dr. Michele Walsh and her collaborators identified improvements in pharmacologic treatment protocols that reduced the duration of opioid exposure in six Children’s hospitals. They next moved to the statewide quality collaborative, the Ohio Perinatal Quality Collaborative, and recruited all level 2 and 3 NICUS in the state to use reliability science methods to improve the care of all newborns and further reduce opioid exposure and duration of hospitalization . Through these prior works, they have accumulated a database that contains over 9,000 opioid exposed neonates. Thus, we are uniquely suited to conduct rapid research that can inform future randomized clinical trials and further improve the care of infants with NAS using 6BN.
DEPENDENCE MODULATORS AS A NEW THERAPEUTIC CLASS
We have now shown that Low Dose 6 Beta Naltrexol (LD-6BN) reaches central opioid receptor sites by slow penetration and long retention in the brain, enabling a possible gradually reversal of upregulated basal MOR activity. LD-6BN appears to act as a dependence modulator rather than a typical opioid antagonist, accounting for its prevention of opioid dependence during agonist treatment, and possibly other aspects of opioid addiction.